Intermittent high glucose promotes expression of proinflammatory cytokines in monocytes

Inflammation Research

Volumn 60, Issue 4, 2011, Pages 367-370

  Yang, Li Bo ^a   Qi, Wen Bo ^a   Lv, Xiao Hong ^a   Feng, You Lun ^a   Zhang, Tie ^a  

^a Taian Central Hospital   (China)

Author keywords

CD11b; IL 6; Intermittent glucose; Monocyte; TNF

Indexed keywords

CD11B ANTIGEN; GLUCOSE; INTERLEUKIN 6; MANNITOL; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ACTIVATION; CELL SURFACE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RESPONSE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; MONOCYTE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

ANTIGENS, CD11B; CELLS, CULTURED; CYTOKINES; GLUCOSE; HUMANS; INTERLEUKIN-6; MONOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955938423     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-010-0279-0     Document Type: Article

References (20)

1. Grundy Scott M, Benjamin Ivor J, Burke Gregory L, Chait Alan, Eckel Robert H, Howard Barbara V, Mitch William, Smith Sidney C Jr, Sowers James R. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-46.
2. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanafeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000;23:1830-4.
3. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study 11-year follow-up. Diabetologia. 1996;39:1577-83. (Pubitemid 26397370)
4. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 1999; 354:617-21.
5. Chiasson Jean-Louis, Josse Robert G, Gomis Ramon, Hanefeld Markolf, Karasik Avraham, Laakso Markku. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-94.
6. Lenters-Westra E, Slingerland RJ. Hemoglobin A1c determination in the A1C-derived average glucose (ADAG) study. Clin Chem Lab Med. 2008;46:1617-23.
7. Raz Itamar, Wilson Peter WF, Strojek Krzysztof, Kowalska Irina, Bozikov Velimir, Gitt Anselm K, Jermendy György, Campaigne Barbara N, Kerr Lisa, Milicevic Zvonko, Jacober Scott J. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32:381-6.
8. Shanmugam Narkunaraja, Reddy Marpadga A, Guha Mausumee, Natarajan Rama. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes. 2003;52:1256-64.
9. Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab. 2001;281:E924-30.
10. Polhill TS, Saad S, Poronnik P, Fulcher GR, Pollock CA. Shortterm peaks in glucose promote renal fibrogenesis independently of total glucose exposure. Am J Physiol Renal Physiol. 2004;287:F268-73.
11. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-72. (Pubitemid 30213096)
12. Ferrari R. The role of TNF in cardiovascular disease. Pharmacol Res. 1999;40:97-105. (Pubitemid 29378088)
13. Nageh Maged F, Sandberg Eric T, Marotti Keith R, Lin Alice H, Melchior Earline P, Bullard Daniel C, Beaudet Arthur L. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1997;17:1517-20.
14. Devaraj S, Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med. 2000;29:790-2.
15. Kulseng B, Skjak-Braek G, Folling I, Espevik T. TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide. Scand J Immunol. 1996;43:335-40. (Pubitemid 26097605)
16. Kunt T, Forst T, Fruh B, Flohr T, Schneider S, Harzer O, Pfutzner A, Engelbach M, Lobig M, Beyer J. Binding of monocytes from normolipidemic hyperglycemic patients with type 1 diabetes to endothelial cells is increased in vitro. Exp Clin Endocrinol Diabetes. 1999;107:252-6. (Pubitemid 29322138)
17. Azuma Kosuke, Kawamori Ryuzo, Toyofuku Yukiko, Kitahara Yoshiro, Sato Fumihiko, Shimizu Tomoaki, Miura Kyoko, Mine Tomoyuki, Tanaka Yasushi, Mitsumata Masako, Watada Hirotaka. Repetitive fluctuations in blood glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta. Arterioscler Thromb Vasc Biol. 2006;26:2275-80.
18. Meerschaert J, Furie MB. Monocytes use either CD11/CD18 or VLA-4 to migrate across human endothelium in vitro. J Immunol. 1994;152:1915.
19. Smith CW, Rothlein R, Hughes BJ, Mariscalco MM, Rudloff HE, Schmalstieg FC, Anderson DC. Recognition of an endothelial determinant for CD18-dependent human neutrophil adherence and transendothelial migration. J Clin Invest. 1988;82(5):1746-56. (Pubitemid 19007781)
20. Wong TY, Phillips AO, Witowski J, Topley N. Glucose-mediated induction of TGF-1 and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. Kidney Int. 2003; 63:1404-16. (Pubitemid 36350005)